跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 27 条关于
“oxyntomodulin”
全部
27
临床试验
6
药物
6
机构
0
资讯
15
去年
Entera Bio and OPKO Health Announce Positive PK/PD Results for Oral Oxyntomodulin for Obesity and Metabolic Disorders
10个月前
MetaVia's DA-1726 Shows Promising Weight Loss Results in Phase 1 Trial with Superior Lipid Benefits
去年
OPKO Health and Entera Bio Collaborate to Develop First Oral GLP-1/Glucagon Dual Agonist for Obesity Treatment
2年前
Altimmune's Pemvidutide Projected to Reach $759M in Global Sales by 2039
去年
OPKO Health and Entera Bio Advance First-in-Class Oral Dual GLP-1/Glucagon Tablet for Obesity Treatment
2年前
NeuroBo Pharmaceuticals Completes Enrollment in Phase 1 Trial of DA-1726 for Obesity
8个月前
MetaVia's DA-1726 Demonstrates 9.1% Weight Loss and Significant Metabolic Benefits in Phase 1b Obesity Trial
去年
Entera Bio Announces Positive Updates on Oral Peptide Programs and Q3 2024 Financial Results
去年
Aphaia Pharma Advances Oral Glucose-Based Obesity Treatment with Second Phase 2 Trial
去年
NeuroBo's DA-1726 Shows Positive Safety and Tolerability in Phase 1 Obesity Trial
第 1 页,共 2 页
上一页
下一页